Pharmacy Guide
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Pharmacy Guide
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Liquivisc 2.5 mg/g, eye gel
⚠ This medicine appears to have been discontinued
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Carbomer may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
What it is and what it is used for
FOR
LIQUIVISC is a substitute for tears and contains a lubricant called Carbomer 974P. It is an eye gel used for the relief of the symptoms of dry eye (such as soreness, burning, irritation or dryness) caused by your eyes not producing enough tears. 2.
BEFORE YOU USE LIQUIVISC
Do NOT use LIQUIVISC: • if you are allergic (hypersensitive) to Carbomer or any of the other ingredients of LIQUIVISC listed in Section 6, "What LIQUIVISC contains". Take special care with LIQUIVISC: • if you wear soft contact lenses: you must remove them before using LIQUIVISC eye gel. After using LIQUIVISC, wait at least 30 minutes before putting your lenses back in. See also in Section 2, "LIQUIVISC contains benzalkonium chloride". • if your condition worsens or has not improved after having started treatment with LIQUIVISC: Contact your doctor. • DO NOT INJECT, DO NOT SWALLOW. Children and adolescents aged to 18 years: The safety and efficacy of LIQUIVISC in children and adolescents at the posology recommended in adults has been established by clinical experience, but no clinical trial data are available. Using other medicines Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription. If you have to use any other eye medicine during treatment with LIQUIVISC: first use the other eye medicine, wait 15 minutes, then use LIQUIVISC.
Pregnancy and breast-feeding If you are pregnant or breast-feeding, contact your doctor for advice before you start using LIQUIVISC. He/she will decide if you can use LIQUIVISC. Driving and using machines Your sight may become blurred for a short time just after using LIQUIVISC. You should not drive or use machines until your sight is clear again. LIQUIVISC contains benzalkonium chloride This medicine contains 0,0015 mg benzalkonium chloride in each drop which is equivalent to 0,06 mg/g. Benzalkonium chloride may be absorbed by soft contact lenses and may change the colour of the contact lenses. You should remove contact lenses before using this medicine and put them back 30 minutes afterwards. Benzalkonium chloride may also cause eye irritation, especially if you have dry eyes or disorders of the cornea (the clear layer at the front of the eye). If you feel abnormal eye sensation, stinging or pain in the eye after using this medicine, talk to your doctor.
3.
How to take it
LIQUIVISC
If LIQUIVISC has been recommended for you then use it exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure. The usual dose of LIQUIVISC is 1 drop in each eye that needs treatment, up to 4 times a day. Children and adolescents aged to 18 years: The safety and efficacy of LIQUIVISC in children and adolescents at the posology recommended in adults has been established by clinical experience, but no clinical trial data are available. Instructions for use Do not use the bottle if the seal around the cap is broken before you first open it. Wash your hands before opening the bottle. Tilt your head back and look at the ceiling.
1. 2. 3. 4.
Gently pull down the lower eyelid of the eye that needs treatment until there is a small "pocket". Turn the bottle upside down. Squeeze it to release 1 drop into the "pocket". Let go of the lower lid, and blink your eyes a few times. Repeat the steps 1 to 3 for the other eye, if it also needs treatment.
To help prevent infection, do not let the tip of the bottle touch your eye, the surrounding tissue or anything else. Put the screw cap back on to close the bottle, straight after you have used it. Store the bottle in an upside down position as this helps drops to form the next time you use LIQUIVISC. Once you have opened the bottle, you must not use it longer than 28 days; please see also Section 5, "How to store LIQUIVISC". If you use more LIQUIVISC than you should Using more drops of LIQUIVISC than you should will not cause you any harm. If you forget to use LIQUIVISC If you have missed a dose of LIQUIVISC continue with your next dose as normal. If you have any further questions on the use of this product, ask your doctor or pharmacist.
4.
Possible side effects
Like all medicines, LIQUIVISC can cause side effects, although not everybody gets them. Contact your doctor if: • your condition worsens or has not improved after having started treatment with LIQUIVISC. If you experience any of the following side effects just after putting in the eye gel, talk to your doctor if they worry you: • short-lived blurring of vision • mild short-lived stinging or feeling of burning in the eye. The above mentioned side effects are known to occur, but the number of people likely to be affected can vary. Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via UK The Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard Ireland HPRA Pharmacovigilance Website: www.hpra.ie By reporting side effects you can help provide more information on the safety of this medicine.
5.
How to store it
LIQUIVISC Keep out of the sight and reach of children. Do not use LIQUIVISC after the expiry date which is stated on the bottle label and the carton after 'EXP.'. The expiry date refers to the last day of that month. Do not store above 25C. Keep the bottle in the outer carton in order to protect from light.
Store the bottle in an upside down position as this helps drops to form the next time you use LIQUIVISC. You must throw away the bottle 28 days after you first opened it, even if there are still some drops left. Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
6.
FURTHER INFORMATION
What LIQUIVISC contains • The active ingredient is Carbomer 974P 2.5 mg/g. • The other ingredients are benzalkonium chloride, sorbitol, lysine monohydrate, sodium acetate trihydrate, polyvinyl alcohol, water for injections. What LIQUIVISC looks like and contents of the pack LIQUIVISC is a slightly yellow opalescent gel in a plastic bottle with a screw-cap. Each bottle contains 10 g of eye gel. Each pack contains 1 bottle. Marketing Authorisation Holder and Manufacturer Marketing Authorisation Holder: Laboratoires Théa 12 rue Louis Blériot 63017 Clermont-Ferrand Cedex 2 FRANCE Manufacturer: URSAPHARM, Arzneimittel GmbH Industriestrasse 66129 Saarbrücken Germany or FARMILA-THEA Farmaceutici S.p.A. Via Enrico Fermi, 50 20019 Settimo Milanese ITALY This medicinal product is authorised in the Member States of the EEA under the following names: France, Spain, Italy, Portugal, The Netherlands and Greece…………………………..SICCAFLUID Ireland…………………………………………………………………………………….LIQUIVISC Iceland and Norway………………………………………………………………………..OFTAGEL
This leaflet was last approved in 03/2025. If you would like any more information, or would like the leaflet in a different format, please contact Medical Information at THEA Pharmaceuticals Ltd in UK, telephone number 345 521 1290, or THEA Pharma Ltd in Ireland, telephone number +44 (0)345 521 1290.
Frequently asked questions about Liquivisc 2.5 mg/g, eye gel
How do I take Liquivisc 2.5 mg/g, eye gel?
Liquivisc 2.5 mg/g, eye gel comes as gel containing 2.5mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
What is the active substance in Liquivisc 2.5 mg/g, eye gel?
The active substance in Liquivisc 2.5 mg/g, eye gel is carbomer.
Where does this information come from?
This leaflet reproduces the patient information leaflet approved for Liquivisc 2.5 mg/g, eye gel, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Can I get Liquivisc 2.5 mg/g, eye gel without a prescription?
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
About this leaflet
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
- Source: electronic medicines compendium (emc), Datapharm
- Active substance: carbomer
- Official document: view the original leaflet on emc →
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
4.1. Therapeutic indications
Symptomatic treatment of dry eye syndrome.
4.2. Posology and method of administration
Ocular use.
Adults (including the elderly):
Instil one drop of the gel into the inferior conjunctival cul-de-sac 1 to 4 times daily according to the degree of ocular trouble.
Children and adolescents aged to 18 years:
The safety and efficacy of LIQUIVISC 2.5 mg/g eye gel in children and adolescents at the posology recommended in adults has been established by clinical experience, but no clinical trial data are available.
After instillation, the bottle should be stored vertically with the dropper downwards to facilitate the formation of drops when next used.
Do not touch the eye with the dropper tip. Replace the cap after use.
4.3. Contraindications
Hypersensitivity to any of the components of the product.
4.4. Special warnings and precautions for use
This medicine contains 0.0015 mg benzalkonium chloride in each drop.
Benzalkonium chloride is commonly used as a preservative in ophthalmic products and has been reported rarely to cause punctate keratopathy and/or ulcerative keratopathy.
Benzalkonium chloride has also been reported to cause eye irritation, symptoms of dry eyes and may affect the tear film and corneal surface. Should be used with caution in dry eye patients and in patients where the cornea may be compromised.
Patients should be monitored in case of prolonged use.
Contact lenses:
Benzalkonium chloride may be absorbed by soft contact lenses and may change the colour of the contact lenses. Patients should be advised to remove contact lenses before using this medicinal product and to wait at least 30 minutes before reinsertion.
4.5. Interaction with other medicinal products and other forms of interaction
In case of concomitant use with other eye drops, wait for 15 minutes between instillations.
LIQUIVISC 2.5 mg/g, eye gel should be the last medication instilled.
4.6. Pregnancy and lactation
LIQUIVISC 2.5 mg/g, eye gel was not studied in pregnant and breast-feeding women.
Caution should be exercised when prescribing to pregnant or breast-feeding women.
4.7. Effects on ability to drive and use machines
Vision may be blurred for a few minutes after the instillation.
If affected, the patient should be advised not to drive or operate hazardous machinery until normal vision is restored.
4.8. Undesirable effects
As for other eye drops, possibility of mild transient stinging or burning upon instillation.
Blurred vision may occur briefly after instillation until the gel is evenly distributed over the eye surface.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme.
Website: www.mhra.gov.uk/yellowcard
4.9. Overdose
Any ocular overdose or oral intake that could occur is of no clinical relevance.
🇵🇱 Known in Poland as
Medicines sold in Poland with the same active substance: W Polsce znany jako
- VidisicCarbomerum · eye / ear / nose
- OftagelCarbomerum · eye / ear / nose
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →
💬 Ask about this leaflet
Ask anything about Liquivisc 2.5 mg/g, eye gel. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.